Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus mFOLFOX6 versus placebo plus mFOLFOX6 in previously untreated metastatic colorectal cancer
2008-005025-11Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) comparing Sorafenib + mFOLFOX6 with Placebo + mFOLFOX6 (2 arms). Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-005025-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005025-11.